首页> 外文期刊>International journal of immunopathology and pharmacology. >Synthesis of a new insulin-mimetic anti-diabetic drug containing vitamin A and vanadium(IV) salt: Chemico-biological characterizations
【24h】

Synthesis of a new insulin-mimetic anti-diabetic drug containing vitamin A and vanadium(IV) salt: Chemico-biological characterizations

机译:包含维生素A和钒(IV)盐的新型胰岛素模拟抗糖尿病药的合成:化学生物学特性

获取原文
       

摘要

Diabetes patients suffer from chronic disorders in the metabolism due to high blood sugar caused by anomalies in insulin excretion. Recently, vanadium compounds have been prepared and functionalized to decrease the level of hyperglycemia. Vitamin A boosts beta cell activity; therefore, the lack of this vitamin plays a role in the development of type 2 diabetes. The aim of this article focused on the synthesis of a new anti-diabetic drug formed from the complexation of a vanadium(IV) salt with vitamin A. Vitamin A acts as a unidentate chelate through the oxygen of its –OH group. The vanadium(IV) compound is surrounded by two vitamin A molecules. The [VO(vitamin A)2(H2O)2] compound was synthesized in a binary solvent system consisting of MeOH/H2O (1:1 ratio) in alkaline media at pH?=?8. This compound was characterized using Fourier transform infrared spectra (FT-IR), electronic spectra (UV–vis), effective magnetic moment, electron spin resonance (ESR), scanning electron microscopy (SEM), transmission electron microscopy (TEM), and thermal analysis (thermogravimetry (TG)–differential thermal analysis (DTA)). Anti-diabetic efficiency for the vanadium(IV) compound was assessed in streptozotocin (STZ)-induced diabetic mice. The results of the animal studies demonstrate the ability of the vanadium(IV) complex to act as an anti-diabetic agent, as measured by improvements of lipid profile, antioxidant activity (superoxide dismutase), malondialdehyde (MDA), glutathione, methionine synthase, and kidney and liver functions.
机译:糖尿病患者由于胰岛素排泄异常引起的高血糖而患有新陈代谢的慢性疾病。最近,已经制备钒化合物并将其官能化以降低高血糖水平。维生素A增强β细胞活性;因此,这种维生素的缺乏在2型糖尿病的发展中起作用。本文的目的集中在由钒(IV)盐与维生素A络合形成的新型抗糖尿病药的合成。维生素A通过其–OH基团的氧起不完全的螯合作用。钒(IV)化合物被两个维生素A分子包围。在由MeOH / H <组成的二元溶剂体系中合成了[VO(维生素A) 2 (H 2 O) 2 ]碱性介质中pH> =?8的sub> 2 O(比例为1:1)。使用傅立叶变换红外光谱(FT-IR),电子光谱(UV-vis),有效磁矩,电子自旋共振(ESR),扫描电子显微镜(SEM),透射电子显微镜(TEM)和热学方法对该化合物进行了表征分析(热重分析(TG)-差热分析(​​DTA))。在链脲佐菌素(STZ)诱导的糖尿病小鼠中评估了钒(IV)化合物的抗糖尿病功效。动物实验结果表明,钒(IV)络合物具有抗糖尿病作用,可以通过改善脂质分布,抗氧化活性(超氧化物歧化酶),丙二醛(MDA),谷胱甘肽,蛋氨酸合酶,和肾,肝功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号